Biotech giant CSL is set to axe almost 3000 jobs globally as it announces a major restructure and savings drive that will see its flu vaccine arm spun off into a separately listed company.
Cheyanne Enciso
WA biotech Emyria will deliver its MDMA-based therapy aimed at treating post-traumatic stress disorder to Brisbane patients after inking a deal with a national mental health hospital operator.
WA biotech Emyria says it’s in talks with other major Australian insurers to fund the use of MDMA-based therapy to treat post-traumatic stress disorder following a landmark deal with Medibank.
Former WA governor and US ambassador Kim Beazley will step down from the board of Perth regenerative medicine company Orthocell due to health reasons.
Investment bank UBS expects Donald Trump’s tariff threat on pharmaceuticals to have ‘limited’ impact on biotech giant CSL, especially if plasma products are excluded.
The peak body for Australia’s life sciences industry has flagged concerns Donald Trump’s pharmaceutical tariff threat could force more local biotechs and medical technology firms to move operations overseas.
The boss of WA regenerative medicine company Orthocell has labelled Donald Trump’s latest tariff threat on pharmaceuticals as a ‘cage-rattling exercise’ to try elicit panic from the Australian Government.
WA biotech Orthocell has posted record revenue for the June quarter as sales for its nerve repair technology surge in Australia, ahead of an expected ramp up in US.
WA regenerative medicine firm Orthocell says it has marked another commercialisation milestone with the first successful surgical use of its nerve repair product in the US.
The Federal Government is pumping $1 million into WA biotech Argenica Therapeutics to advance global clinical trials for its potentially life-saving stroke drug.
Australia’s biggest health insurer is backing the use of MDMA-based therapy to treat post-traumatic stress disorder in a landmark deal signed with a WA-based biotech.
Orthocell says it has moved at ‘warp speed’ to secure US distributors for its nerve repair device, marking another milestone in its commercialisation push into the world’s biggest healthcare market.
WA diagnostics startup BlinkLab has raised nearly $8 million to bankroll a clinical trial for its smartphone autism test ahead of a US Food And Drug Administration submission.
Orthocell has added Canada to its string of regulatory approvals for its flagship nerve repair product.
WA biotech Orthocell has received the green light to start selling its nerve repair product into the Thai market, worth $131 million.
WA regenerative medicine company Orthocell has posted a near-40 per cent jump in fourth quarter revenue just days after it won a major regulatory clearance in the US.
US President Donald Trump has signalled a tariff on imported pharmaceuticals, a policy that is expected to directly hit Australia’s second-largest export to the US.
Jackson Hewett
PYC Therapeutics is facing a $13 million hole as one of its underwriters struggle to fill its share of a shortfall from the biotech’s $146m equity raising.
Orthocell has approval to start selling its dental bone repair product into the $US65 million ($109m) Brazilian market.
A group of WA biotechs have urged the State Government to match the existing Federal research and development tax incentive in a move they are certain will attract and retain talent.
WA biotech Orthocell says there’s no need to shift production to the US to dodge Donald Trump’s tariffs as it wins clearance from the Food and Drug Administration to start selling its nerve repair product.
WA biotech Neurotech has secured the backing of the European Commission for its oral cannabinoid drug therapy aimed at treating Rett syndrome, a rare genetic disorder affecting the way the brain develops.
The biotech says its potentially life-saving drug is drawing increasing interest from major pharmaceutical companies in China, where stroke is now the leading cause of death.
WA biotech PYC Therapeutics is tapping shareholders for up to $146 million to fund the development of its four drug candidates.
We use cookies so we can improve your experience on this site, analyse traffic and provide you with relevant advertising. To find out more, please see our Cookies Guide.
By continuing to use this site, you agree to our use of cookies.